Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome
To evaluate the effect of RAS-MAPK pathway inhibitor Trametinib on medically refractory chylous effusions in three hospitalized patients with Noonan syndrome.
source https://www.jpeds.com/article/S0022-3476(22)00479-6/fulltext?rss=yes
source https://www.jpeds.com/article/S0022-3476(22)00479-6/fulltext?rss=yes
Comments
Post a Comment